The Jreissati Family Pancreatic Centre at Epworth runs research studies and clinical trials covering every phase of patient diagnosis, treatment and care. The goal is to improve patient outcomes and quality of life for patients with pancreatic cancer.

Clinical trials are vital if we are to improve the survival rate for patients with pancreatic cancer. But what are they?

Need help?

Talk to our pancreatic nurse coordinator 

Your pancreatic nurse coordinator will be your first point of contact during your treatment journey at Epworth. They will be able to provide answers to any questions that your or your family may have.
GP referral

Get referred

Once referred to the Jreissati Family Pancreatic Centre at Epworth, you will have an appointment to see one of our experienced specialists within 72 hours.
Clinical research is vital to improving outcomes for patients with pancreatic cancer. These research studies can be observational studies that involve collecting data on a disease's trajectory to better understand it. They can also be interventional to determine whether an experimental treatment is safe and effective. The main goal of clinical trials is to see if discoveries made during the research phase are better than current treatment options.

For clinical trials, volunteer participation is essential. Results from trials will help determine if new treatments for pancreatic cancer work and if there are side effects. They're also an effective way for patients to gain access to the latest treatment options. Participation leads to advances in research, better treatments, and better patient outcomes.

When deciding if you want to take part in a clinical trial, you need to be aware of what the trial involves. You should also seek advice from your specialist before taking part. At Epworth, there are a number of clinical studies that are open to people with pancreatic cancer and are listed below.

Pancreatic cancer research at the Jreissati Family Pancreatic Centre at Epworth

Current clinical trials and special access schemes

Listing updated: 8 February 2022

Diagnosis; Line Trial ID and Status Study Title Locations Contact
Metastatic
pancreatic cancer 

(Stage IV)

1st and 2nd line
NCT04481009

Recruiting
YH003004

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC)

 
Epworth Freemasons
Epworth Richmond
 
A/Prof Sumitra Ananda
Resectable
pancreatic cancer

(Stage I-II)

1st line 
ACTRN12618000335291

Recruiting
DYNAMIC-Pancreas

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study.
Epworth Freemasons
Epworth Richmond
 
Dr Ross Jennens
Unresectable locally advanced
pancreatic cancer

(Stage III)

Neo-adj
NCT03899636

Recruiting
DIRECT-InspIRE

A Multicentre, Open-label, Innovation Study in Pancreatic Cancer Utilising the NanoKnife® System for Irreversible Electroporation (IRE) in Unresectable Stage 3 Pancreatic Adenocarcinoma

 
Epworth Freemasons Mr Brett Knowles
Metastatic
pancreatic cancer

(Stage IV)

1st line
ACTRN12621001290886

Recruiting
ASCEND

A randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma
Epworth Freemasons
Epworth Richmond
 
Dr Ross Jennens
Unresectable locally advanced
pancreatic cancer

(Stage III)
Special access scheme

Taking referrals
OncoSil 

Epworth is an accredited OncoSil treatment facility

 
Epworth Richmond A/Prof Andrew Metz
Dr Peter Tagkalidis

Current research studies 

These studies may ask participants for permission to store their cancer sample, or take part in non-treatment research. Please get in touch using the online form, email or phone listed on the contact us page to take part in advancing research.  

Diagnosis Project ID and Status  Study Details  Locations  Contact 
Individuals at high risk of developing pancreatic cancer (based on demographics and family history) EH2021-666

Recruiting
APCSP

The Australian Pancreatic Cancer Screening Program: Screening for pancreatic cancer in high risk individuals
All Epworth sites A/Prof Andrew Metz 
Suspected diagnosis of pancreatic cancer or cholangiocarcinoma EH689-15

Recruiting
VPCB

The Victorian Pancreatic Cancer Biobank
Epworth Richmond Dr Peter Tagkalidis
Suspected diagnosis of pancreatic or colorectal cancer EH2019-481

Recruiting
Organoid Biobank

Establishing biobanks of colorectal and pancreatic cancer models for the pursuit of personalised therapies
Epworth Richmond Mr Brett Knowles 
Pancreatic cancer EH2021-694

Recruiting
EU-ME-PC

The Endoscopic Ultrasound Molecular Evaluation of Pancreatic Cancer (EU-ME-PC): A Prospective Multicentre Cohort Trial
All Epworth sites Dr Allan Zimet 
Pancreatic cancer Recruiting MoST

Molecular Screening and Therapeutics program
All Epworth sites A/Prof Andrew Metz 
Unresectable pancreatic cancer EH2020-661

Recruiting
OSCILLATE

An Observational Study following Circulating tumour DNA during multi-Agent Therapy in PDAC (OSCILLATE): a hypothesis-generating, prospective cohort study
Epworth Freemasons
Epworth Richmond
Epworth Eastern
Dr Allan Zimet
Primary carer of patient with pancreatic cancer EH2021-729

Recruiting
 
PRoCESS

Pancreatic Cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling on participant-reported outcomes and use of medical services.
All Epworth sites A/Prof Andrew Metz
Newly diagnosed pancreatic cancer New study

Recruiting
 
PATHWAYS

Pancreatic cancer pathways to diagnosis
All Epworth sites A/Prof Andrew Metz

Databases and registries

These projects ask participants for permission to record treatment data to build better knowledge of pancreatic cancer care. Please get in touch using the online form, email or phone details on the contact us page if you see you or your patient’s diagnosis listed below.

Diagnosis Project ID and Status  Study Details  Locations  Contact 
Newly diagnosed upper GI cancer EH2017-227

Recruiting
UGICR

Upper Gastrointestinal Cancer Registry
Epworth Freemasons
Epworth Richmond
Epworth Eastern
Mr Brett Knowles
Newly diagnosed pancreatic cancer ACTRN12617001474347 


Recruiting
PURPLE

Pancreatic cancer: Understanding Routine Practice and Lifting End Results. A Prospective Pancreatic Cancer Clinical Registry
Epworth Freemasons
Epworth Richmond
Epworth Eastern
A/Prof Rachel Wong
Intraductal papillary mucinous neoplasm (PPMN) EH2021-731

Recruiting
IPMN

IPMN Database – A tool to predict pancreatic cancer
Epworth Eastern A/Prof Andrew Metz
Pancreatic cancer EH2021-768

New study

Recruiting
PAN-ExPERT

Pancreatic enzyme replacement therapy in pancreatic cancer: An implementation strategy
Epworth Richmond Mr Mark Cullinan
Pancreatic or oesophageal cancer Recruiting PROpatient

PROpatient - A registry-based randomised controlled trial (RRCT) of symptom monitoring, using patient-reported outcomes
All Epworth sites Mr Brett Knowles

Phone: 03 9426 8880
Email: [email protected]